Patents Assigned to ZARODEX THERAPEUTICS LIMITED
  • CLOZAPINE FOR THE TREATMENT OF A IMMUNOGLOBULIN DRIVEN B CELL DISEASE
    Publication number: 20210236512
    Abstract: This invention relates to the compound clozapine and its major metabolite norclozapine and prodrugs thereof and pharmaceutically acceptable salts and solvates thereof for use in the treatment or prevention of a pathogenic immunoglobulin driven B cell disease with a T cell component. The invention also provides pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: January 31, 2019
    Publication date: August 5, 2021
    Applicant: ZARODEX THERAPEUTICS LIMITED
    Inventors: Stephen JOLLES, Houman ASHRAFIAN, Duncan MCHALE
  • NOVEL USES
    Publication number: 20210236513
    Abstract: This invention relates to the compound clozapine and its major metabolite norclozapine and prodrugs thereof and pharmaceutically acceptable salts and solvates thereof for use in the treatment or prevention of a pathogenic immunoglobulin driven B cell disease. The invention also provides pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: January 31, 2019
    Publication date: August 5, 2021
    Applicant: ZARODEX THERAPEUTICS LIMITED
    Inventors: Stephen JOLLES, Houman ASHRAFIAN, Duncan MCHALE
  • CLOZAPINE FOR THE TREATMENT OF IG-E DRIVEN B CELL DISEASES
    Publication number: 20210137941
    Abstract: This invention relates to the compound clozapine and its major metabolite norclozapine and prodrugs thereof and pharmaceutically acceptable salts and solvates thereof for use in the treatment or prevention of a pathogenic IgE driven B cell disease. The invention also provides pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: January 31, 2019
    Publication date: May 13, 2021
    Applicant: ZARODEX THERAPEUTICS LIMITED
    Inventors: Stephen JOLLES, Houman ASHRAFIAN, Duncan MCHALE